Three letters organize a blood test result for millions of people worldwide who will never develop cancer: MGUS. Robert A. Kyle, MD, the Mayo Clinic hematologist who defined and named that condition, died September 4, 2026, according to the International Myeloma Foundation, at age 98. He had lived in Rochester, Minnesota, for more than six decades.

Kyle was born March 17, 1928, in Bottineau, North Dakota, and grew up with four brothers on a farm six miles outside town, where a single teacher taught fifteen to twenty children across all eight grades in one schoolroom, according to The ASCO Post. He completed two years at the North Dakota School of Forestry in Bottineau, finished his degree at the University of North Dakota in Grand Forks in 1948, and graduated with distinction from Northwestern University Medical School in Chicago in June 1952. Drafted into the U.S. Air Force in 1955, he served two years in Alaska, then trained in hematology, first at Mayo Clinic and then for two years at Tufts University in Boston under William Dameshek, MD, one of the era's leading clinical hematologists.

He joined Mayo Clinic's staff in Rochester in August 1961 and stayed for the rest of his working life. What he pursued there, patiently and without interruption, was one question: which patients with an abnormal blood protein would go on to develop cancer, and which would not. Answering it meant tracking the same patients for years, sometimes decades, a discipline that became the defining thread of his career.

That discipline produced his signature contribution. In a 1978 paper in the American Journal of Medicine that followed 241 patients with an unexplained monoclonal protein in their blood but no sign of malignancy, Kyle proposed a new diagnostic category: monoclonal gammopathy of undetermined significance, or MGUS. Two years later, working with Mayo colleague Philip Greipp, MD, he described a symptom-free, higher-risk stage between MGUS and active disease in the New England Journal of Medicine, coining the term smoldering multiple myeloma. Both terms remain standard vocabulary in hematology clinics worldwide, used daily to decide which patients need only monitoring and which need treatment.

He spent the following decades building institutions around that discovery as much as extending it. He served as Section Head and later Chairman of Mayo's Division of Hematology and chaired the Myeloma Committee of the Eastern Cooperative Oncology Group for twelve years, according to the International Myeloma Society, where he became the organization's first president. He was also the first president of the International Society of Amyloidosis and chaired the founding Scientific Advisory Board of the International Myeloma Foundation. Across his career he authored more than 1,050 scientific articles and over 1,350 additional abstracts and editorials on myeloma and related plasma cell disorders.

The honors followed the work. He was the first recipient of the Waldenstrom's Award in 2001, received the David A. Karnofsky Award from the American Society of Clinical Oncology in 2007, and won the Wallace H. Coulter Award for Lifetime Achievement from the American Society of Hematology in 2008, making him the only physician to hold both of those top individual honors in oncology and hematology. Northwestern's Feinberg School of Medicine named him a Distinguished Alumnus in 2013, and the American College of Physicians gave him its John Phillips Award in 2015.

Colleagues remembered him as much for how he trained people as for what he discovered. Ruben Mesa, MD, president of Atrium Health Levine Cancer, recalled his first day as a Mayo fellow, when the legendary Bob Kyle stopped what he was doing to personally show him how to read an SPEP and regale him with stories of challenging cases, calling Kyle "the very definition of a servant leader, gentleman clinician, and a mentor to generations." S. Vincent Rajkumar, MD, chairperson of the IMF's board, said his legacy could be seen "in the countless myeloma experts who consider him as their mentor," and IMF president and CEO Heather Cooper Ortner called him "a trusted mentor, colleague, and friend to generations of myeloma researchers and clinicians."

Kyle was married to Charlene for 70 years. He made his first gift to his undergraduate alma mater, the University of North Dakota, in April 1962, and gave annually for more than 62 consecutive years, according to UND. He and Charlene later endowed a scholarship at Northwestern's Feinberg School of Medicine. Asked why he kept giving, he said simply, "I believe in philanthropy. To the best of my ability, I have designated money to support causes that are important to me." As recently as 2022, at 94, he still kept an office at Mayo Clinic, no longer seeing patients but still reviewing cases and mentoring younger hematologists, and was at work on a memoir.

What persists is the vocabulary he built and the patients it protects. A physician anywhere in the world who tells a patient their blood test shows MGUS, not cancer, and orders a follow-up test instead of chemotherapy, is applying a framework Kyle spent 65 years at Mayo Clinic proving out, one tracked patient at a time. The scholarship he and Charlene funded in Chicago and the six decades of unbroken giving to his North Dakota alma mater continue to underwrite the kind of one-room-schoolhouse-to-medical-school path he traveled himself, and the Lifetime Achievement Award established in his name at the International Myeloma Foundation continues to go, each year, to a clinician who treats myeloma patients with the same patience he did.